|KOMISJA NADZORU FINANSOWEGO|
|Raport bieżący nr||3||/||2020|
|Skrócona nazwa emitenta|
|Receiving a Notice of Allowance for U.S Patent related to Cosmetic Injection System|
|Art. 17 ust. 1 MAR - informacje poufne.|
| The Board of Directors of Milestone Medical Inc. (WAR: MMD, “the Company”, “the Issuer”), today announced that Milestone Scientific, Inc., (NYSE: MLSS), the majority shareholder and licensor of Milestone Medical Inc., has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a U.S. patent regarding a new application for its technology in which claims were allowed for a Computer Controlled Drug Infusion Device for cosmetic use. The allowed claims relate to a novel cosmetic injection instrument for the delivery of botulinum toxin, such as Botox® and Dysport®.
The CompuFlo® system with DPS Dynamic Pressure Sensing (DPS®) Technology® provides an objective tool that can consistently reduce pain perception, accurately maintain a precise unit dose of botulinum toxin and allows the graphic recording of unit doses for each patient, while allowing the clinician to generate a precise record for future use. Additionally, the patented hand piece design provides for greater tactile feel for precise needle manipulation and placement. The system is optimized for a faster, more precise and virtually painless experience for the patient while providing clinicians with an important graphic recording of the procedure.
The Board of Directors of the Company is pleased to receive the Notice of Allowance related to the cosmetic injection system, as this expands the intellectual property into an exciting new application. Based on the Issuer’s previous feasibility study of plastic surgeons and cosmetic dermatologists, the Company recognized the profession’s interest in a new cosmetic injection system that would allow the delivery of precise dosage and address the need for a unique graphic record.
With this patent in hand, The Board of Directors of the Company looks forward to advancing the commercial roll-out of the cosmetic injection instrument in the U.S., which has the potential to significantly impact the safety and administration of botulinum toxin. The market opportunity for the cosmetic instrument includes over 8.4 million botulinum toxin injections delivered annually in the U.S. alone.
|MESSAGE (ENGLISH VERSION)|
|PODPISY OSÓB REPREZENTUJĄCYCH SPÓŁKĘ|
|Data||Imię i Nazwisko||Stanowisko/Funkcja||Podpis|
|2020-01-20||Joseph D'Agostino||Chief Financial Officer||Joseph D'Agostino|
Źródło: GPW - komunikaty spółek (ESPI)